Juvenile Arthritis News

Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release.

The mortality risk for a 35-year-old patient with a rare autoimmune rheumatic disease during the COVID-19 pandemic is similar to that of a 55-year-old in the general population, according to UK data published in Rheumatology.

Depression, anxiety and suicide ideation are all elevated in pediatric and adolescent rheumatology populations compared with the general population, according to a presenter at ACR Convergence 2020.

Despite minimal evidence available, authors of the 2020 ACR juvenile idiopathic arthritis guidelines emerged with nearly 50 recommendations, emphasizing early use of biologics, regular immunizations and reduced reliance on corticosteroids.

Patients with polyarticular-course juvenile idiopathic arthritis achieved high-level disease control for up to 2 years when treated with tocilizumab, according to data published in Arthritis & Rheumatology.

Advances in understanding of systemic juvenile idiopathic arthritis and adult-onset Still’s disease have elucidated the impact of biologic therapies on these conditions, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.

The FDA has approved Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis in patients aged 2 years and older, while also expanding its psoriatic arthritis indication for this patient population, according to a press release from Janssen.

The FDA has approved Xeljanz in tablet and oral formulations for the treatment of polyarticular course juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Pfizer.

The emergence of a multisystem inflammatory syndrome in children with COVID-19 has forced pediatric rheumatologists to elevate the understanding of inflammatory events in their patients, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

Tapering canakinumab in patients with systemic juvenile idiopathic arthritis who achieve remission may be feasible but holding this response may require consistent IL-1 inhibition, according to data published in Arthritis & Rheumatology.